about
Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignanciesInternational Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG).Worldwide Esophageal Cancer Collaboration: pathologic staging data.Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data.Worldwide Esophageal Cancer Collaboration: clinical staging data.Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002.Laparoscopic Nissen fundoplication--200 consecutive casesGenomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis.Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus.Relapse patterns after chemo-radiation for carcinoma of the oesophagus.Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma.TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).A systematic review of non-surgical treatments for lentigo maligna.Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.Salvage definitive chemo-radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: retrospective review.Minimally invasive esophagectomy: an overview.Neoadjuvant chemotherapy or chemoradiotherapy for locally advanced esophageal cancer.Controversies in the management of gastrointestinal stromal tumors.Molecular markers to complement sentinel node status in predicting survival in patients with high-risk locally invasive melanoma.Building a sustainable clinical academic workforce to meet the future healthcare needs of Australia and New Zealand: report from the first summit meeting.Construction and management of ileostomies and colostomies.Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.Assessment of morbidity following regional nodal dissection in the axilla and groin for metastatic melanoma.TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma.Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia.Outcome predictors in median arcuate ligament syndrome.BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases - results of a prospective, non-randomized, single-centre study.Long-term Health-related Quality of Life Following Esophagectomy: A Nonrandomized Comparison of Thoracoscopically Assisted and Open Surgery.Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.Australian Multicenter Study of Isolated Limb Infusion for Melanoma.Results of a phase II, open-label, non-comparative study of intralesional PV-10 followed by radiotherapy for the treatment of in-transit or metastatic melanoma.Primary cutaneous melanoma of the scalp: Patterns of recurrence.Use of support services in a sample of patients with high-risk primary melanomas in urban, regional and rural Queensland.Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.Availability of organs for transplantation: a three year study.Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.No role for melanoma treatment in the association between melanoma and amyotrophic lateral sclerosis or Parkinson's disease.Symptomatic and functional outcome after laparoscopic reoperation for failed antireflux surgery.
P50
Q28344330-D05DBB7B-3E75-4275-AB80-542F5F503940Q30885409-C11C7A2E-FD69-4AA6-BEE7-6AED85130AF3Q31136227-535BE084-E3D4-4A27-B42F-2F28D7F20992Q31136229-9ACB1758-005D-454C-9C15-F6232A3C9581Q31136233-77A1B06B-71F5-4B7C-A0F4-E574228547F0Q33992904-A3F28929-EB55-4DBC-9612-C6980D5929B0Q34409516-98034658-5658-4DDB-B70C-FDD034D56E3DQ34445264-636F67D3-E074-415F-AEDC-E0A5C9A986BFQ34691502-1E2DE79C-B382-4DAA-8B5E-FBD251B17587Q35151818-463729BB-845B-472F-81B3-6FCE3AA2956BQ35690688-6F6733E7-527F-4164-BB04-CAFF52EAF7EEQ35700920-0EA0AFCF-1443-4FE6-B599-BA7B51CC532DQ35753267-02698189-D6E4-4594-97BC-7614D9F42639Q37229247-15F429AD-B3D4-468C-B753-310744126428Q37380069-4D79B043-FB37-427D-9BA9-07F743C91E0CQ37688139-3517E555-4E72-41A7-AB1F-062135778611Q38160522-116CC501-FFE3-4AC9-A47D-6E705BB9C5EAQ38199797-B0BE94BF-DFFE-44F1-8E32-3F03461851A1Q38381558-0E3266FE-E57D-426D-86F7-B9A77266412DQ38579135-A53FE772-FE57-4B3A-9A66-5007F4D67D35Q38679175-10B23FD4-6E0A-4141-A75D-BBA9F8338EEFQ38738044-3973226A-E4D7-425B-8CD5-9931EB5566E2Q38877852-DA5BED2D-6D6D-47FD-8B5F-9A7223C0A826Q38880523-930DCD17-2212-4C91-8247-7DF2D66D0A63Q38948856-20CADB0D-FE2C-4216-BDC8-551FB2DD3D53Q39106275-B376180F-77FE-43B8-8B8C-B9ACBFACAB27Q39131636-AC986581-28AA-4B2B-BEB0-03B5C93FFC2DQ39152540-7A291659-F6AF-411A-8C5C-E311302F2563Q39381921-61D26AE6-AC4B-48C2-B8ED-018E3560905EQ39590531-E6D82082-58E9-4DB0-BBAF-8DE4E712250DQ39737918-AAEEC25E-0D54-4AC3-9A6B-0E09D1083E7FQ40307423-2C445296-716B-4E22-954B-7B277B6BFB21Q40322347-A2C65D12-BB03-4949-9325-A29FB9714075Q40402096-69CBEBEC-6DA7-44B9-9E94-7EB66C3C2329Q40458333-FABFA30B-ABD1-4C3D-BD92-80FF013A2FEFQ40701951-07F688A9-B96E-4D83-84BC-8238986B9D3EQ41808469-C6AA53FF-5BD5-4924-95D6-618121677B9FQ42376753-477B2BD8-4AD9-4A4D-9B68-4C7908EA9C14Q42379481-F30BAFC0-A18C-4478-8F31-2F8F66C6DE56Q42661555-6ED9CFCF-EC8B-4867-926F-C5DCDD551FEB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark Smithers
@ast
Mark Smithers
@en
Mark Smithers
@es
Mark Smithers
@nl
type
label
Mark Smithers
@ast
Mark Smithers
@en
Mark Smithers
@es
Mark Smithers
@nl
prefLabel
Mark Smithers
@ast
Mark Smithers
@en
Mark Smithers
@es
Mark Smithers
@nl
P106
P1153
7003516470
P31
P496
0000-0002-8333-8685